Daniel Barlow, MD
Family Medicine · Opelika, ALNPI 1457738338
Payments from drug & device makers
Across 139 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$444
- Novo Nordisk$261
- AstraZeneca$250
- Pfizer$228
- Otsuka America Pharmaceutical, Inc.$131
- Bayer$124
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,514100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $444 |
| Novo Nordisk | 13 | $261 |
| AstraZeneca | 11 | $250 |
| Pfizer | 15 | $228 |
| Otsuka America Pharmaceutical, Inc. | 6 | $131 |
| Bayer | 7 | $124 |
| Abbott | 6 | $113 |
| Ardelyx, Inc. | 4 | $85 |
| Lilly USA, LLC | 5 | $82 |
| Novartis | 5 | $79 |
| GSK | 6 | $77 |
| Vanda Pharmaceuticals Inc. | 3 | $75 |
| Amgen | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $63 |
| Boehringer Ingelheim | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Edwards Lifesciences | 1 | $44 |
| Mylan Specialty L.p. | 2 | $39 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $35 |
| Corcept Therapeutics | 2 | $33 |
| Radius Health, Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $25 |
| Tris Pharma Inc | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Boston Scientific | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Eisai Inc. | 1 | $12 |
How this compares
$2,514 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 184 | $208,024 |
| JardianceEmpagliflozin | 42 | $65,331 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $60,796 |
| FarxigaDapagliflozin Propanediol | 51 | $60,788 |
| OzempicSemaglutide | 47 | $60,317 |
| EliquisApixaban | 41 | $53,504 |
| TrulicityDulaglutide | 42 | $53,425 |
| RybelsusSemaglutide | 16 | $37,238 |
| EntrestoSacubitril/Valsartan | 23 | $25,649 |
| JanuviaSitagliptin Phosphate | 15 | $23,940 |
| LinzessLinaclotide | 28 | $22,663 |
| MyrbetriqMirabegron | 18 | $13,405 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $13,301 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $13,290 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $10,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $82 | $261,449226 claims |
| Novo NordiskOzempic, Rybelsus | $261 | $97,55563 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $62 | $88,92184 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $77 | $80,994133 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $250 | $65,75163 claims |
| PfizerEliquis | $228 | $53,50441 claims |
| NovartisEntresto | $79 | $25,64923 claims |
| AbbVieLinzess | $444 | $22,66328 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $13,40518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Opelika
- Sunil SharmaOpelika$17K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.